CA2422916A1 - Compounds and methods for use thereof in the treatment of cancer or viral infections - Google Patents

Compounds and methods for use thereof in the treatment of cancer or viral infections Download PDF

Info

Publication number
CA2422916A1
CA2422916A1 CA002422916A CA2422916A CA2422916A1 CA 2422916 A1 CA2422916 A1 CA 2422916A1 CA 002422916 A CA002422916 A CA 002422916A CA 2422916 A CA2422916 A CA 2422916A CA 2422916 A1 CA2422916 A1 CA 2422916A1
Authority
CA
Canada
Prior art keywords
alkyl
alkoxy
compound
compounds
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002422916A
Other languages
English (en)
French (fr)
Inventor
James C. Quada, Jr.
Joseph K. Agyin
James Berger Camden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAF Technologies and Research LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/670,168 external-priority patent/US6462062B1/en
Priority claimed from US09/670,169 external-priority patent/US6407105B1/en
Priority claimed from US09/670,170 external-priority patent/US6380232B1/en
Priority claimed from US09/670,166 external-priority patent/US6608096B1/en
Application filed by Individual filed Critical Individual
Publication of CA2422916A1 publication Critical patent/CA2422916A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002422916A 2000-09-26 2001-09-19 Compounds and methods for use thereof in the treatment of cancer or viral infections Abandoned CA2422916A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US09/670,168 US6462062B1 (en) 2000-09-26 2000-09-26 Compounds and methods for use thereof in the treatment of cancer or viral infections
US09/670,169 2000-09-26
US09/670,168 2000-09-26
US09/670,169 US6407105B1 (en) 2000-09-26 2000-09-26 Compounds and methods for use thereof in the treatment of cancer or viral infections
US09/670,170 US6380232B1 (en) 2000-09-26 2000-09-26 Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US09/670,166 2000-09-26
US09/670,170 2000-09-26
US09/670,166 US6608096B1 (en) 2000-09-26 2000-09-26 Compounds and methods for use thereof in the treatment of cancer or viral infections
PCT/US2001/029261 WO2002026716A2 (en) 2000-09-26 2001-09-19 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections

Publications (1)

Publication Number Publication Date
CA2422916A1 true CA2422916A1 (en) 2002-04-04

Family

ID=27505337

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002422916A Abandoned CA2422916A1 (en) 2000-09-26 2001-09-19 Compounds and methods for use thereof in the treatment of cancer or viral infections

Country Status (6)

Country Link
EP (1) EP1330441A2 (ja)
JP (1) JP2004509949A (ja)
AU (2) AU9279601A (ja)
CA (1) CA2422916A1 (ja)
MX (1) MXPA03002601A (ja)
WO (1) WO2002026716A2 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG129306A1 (en) 2000-09-11 2007-02-26 Chiron Corp Quinolinone derivatives as tyrosine kinase inhibitors
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
AU2003220585A1 (en) 2002-03-26 2003-10-13 Arizona Board of Regents on behalf of the University of Arizone Solubilization of weak bases
US7205412B2 (en) * 2002-07-03 2007-04-17 Samsung Electronics Co., Ltd. Antibiotic additive and ink composition comprising the same
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
JP2004115397A (ja) * 2002-09-25 2004-04-15 Fuji Photo Film Co Ltd 血管疾患治療薬を含むリポソーム
WO2005094897A2 (en) * 2004-04-01 2005-10-13 Cardiome Pharma Corp. Pegylated ion channel modulating compounds
EP1888556B1 (en) 2005-05-17 2011-10-26 Novartis AG Methods for synthesizing heterocyclic compounds
WO2010074588A2 (en) * 2008-12-24 2010-07-01 BIAL - PORTELA & Cª, S.A. Pharmaceutical compounds
KR101064258B1 (ko) 2008-12-29 2011-09-14 한국과학기술연구원 벤조아릴우레이도 화합물, 및 이를 함유하는 퇴행성 뇌질환예방 또는 치료용 조성물
CN103450093A (zh) * 2013-09-06 2013-12-18 中国药科大学 2-苄氨基苯并咪唑类化合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399212A (en) * 1966-05-16 1968-08-27 Smith Kline French Lab Benzimidazole ureas
US3480642A (en) * 1967-03-22 1969-11-25 Smithkline Corp Process for producing 2-carbalkoxyaminobenzimidazoles
DE2253324A1 (de) * 1972-10-31 1974-05-09 Bayer Ag 1-alkoxycarbonyl-2- eckige klammer auf bis-(alkoxycarbonyl)-amino eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung, sowie ihre verwendung als fungizide
HU177582B (en) * 1977-10-25 1981-11-28 Chinoin Gyogyszer Es Vegyeszet Fungicide preparations containing new benzimidazole derivatives and process for preparing the active materials thereof
ZA962879B (en) * 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
PE11499A1 (es) * 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer

Also Published As

Publication number Publication date
JP2004509949A (ja) 2004-04-02
MXPA03002601A (es) 2005-02-25
EP1330441A2 (en) 2003-07-30
WO2002026716A2 (en) 2002-04-04
WO2002026716A3 (en) 2002-07-11
AU9279601A (en) 2002-04-08
AU2001292796B2 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
US6420411B1 (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
US20050288348A1 (en) Compounds and methods for use thereof in the treatment of cancer
US6498188B1 (en) Methods of treatment for cancer or viral infections
US6136835A (en) Methods of treatment for viral infections
US6265427B1 (en) Pharmaceutical composition for the method of treating leukemia
CA2863330C (en) Therapeutic benzimidazoyl agents
US6380232B1 (en) Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US10189797B2 (en) Chemical modulators of immune checkpoints and therapeutic use
CA2380414C (en) Method of cancer treatment
AU2001292796B2 (en) Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections
FI71556C (fi) Foerfarande foer framstaellning av 5-(paradeuterofenyl)-5-fenylhydantoin, vilken aer ett laekemedel anvaendbart mot konvulsioner.
AU2001292796A1 (en) Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
JP6860677B2 (ja) グローコカリキシンａ誘導体、その医薬的に許容できる塩または医薬組成物、およびこれらの乾癬治療用医薬の調製における使用
US20010002403A1 (en) N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
CN114096524A (zh) 用于治疗癌症、抑制趋化因子活性和/或诱导细胞死亡的小分子

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead